Antibiotics for UTI in Pregnancy: Which Are Safe and Effective?

TL;DR

• Urinary tract infections affect 2–10% of pregnancies and require prompt treatment — even when asymptomatic — to prevent pyelonephritis and preterm birth.
• First-line options include cephalexin, amoxicillin-clavulanate, and fosfomycin, which carry favorable safety profiles across all trimesters.
• Nitrofurantoin is effective but warrants caution in the first trimester (possible teratogenicity) and near term (≥36 weeks; neonatal hemolytic anemia risk).
• Fluoroquinolones and trimethoprim-sulfamethoxazole are generally avoided throughout pregnancy.
• All pregnant patients should be screened for asymptomatic bacteriuria at 12–16 weeks (ACOG, USPSTF Grade A recommendation).

§01Why UTI in Pregnancy Demands Special Attention

Urinary tract infections are among the most common bacterial infections encountered during pregnancy. Physiological changes — progesterone-mediated ureteral smooth-muscle relaxation, mechanical compression of the ureters by the enlarging uterus, and increased bladder residual volume — create an environment that promotes bacterial colonization and ascending infection. A UTI antibiotic pregnancy safe approach must balance effective bacterial eradication against fetal exposure risk.

The clinical spectrum ranges from asymptomatic bacteriuria (ASB), present in 2–10% of pregnancies, to acute cystitis and pyelonephritis. What distinguishes the pregnant population is the high rate of progression: untreated ASB advances to pyelonephritis in 20–40% of cases, compared with fewer than 2% in non-pregnant women. Pyelonephritis during pregnancy is associated with sepsis, acute respiratory distress syndrome, preterm labor, and low birth weight.

For these reasons, both the American College of Obstetricians and Gynecologists (ACOG) and the United States Preventive Services Task Force (USPSTF) recommend universal screening for ASB with urine culture at 12–16 weeks of gestation, followed by antibiotic treatment of all positive cultures (≥10⁵ CFU/mL of a single uropathogen).

§02Microbiology and Resistance Patterns

Understanding the causative organisms informs empirical antibiotic selection. The bacteriology of UTI in pregnancy mirrors that of uncomplicated UTI in non-pregnant women:

Key clinical point: Local antibiograms should guide empirical therapy. In regions where E. coli ampicillin resistance exceeds 20%, amoxicillin monotherapy is no longer a reliable empirical choice. Culture and sensitivity testing remain essential, particularly for treatment failures or recurrent infections.

§03Evidence-Based Antibiotic Options: Head-to-Head Comparison

Four antibiotics dominate the evidence for UTI treatment in pregnant women: nitrofurantoin, cephalexin, amoxicillin-clavulanate, and fosfomycin. Each has distinct advantages and limitations across trimesters.

Comparison Table

Nitrofurantoin — The First-Trimester Debate

Nitrofurantoin remains one of the most prescribed agents for lower UTI in pregnancy, but its safety profile requires nuanced discussion:

• First trimester: The National Birth Defects Prevention Study (NBDPS) identified a modest association between first-trimester nitrofurantoin use and certain cardiac and orofacial malformations (adjusted OR approximately 1.5–2.0 for select defects). However, the absolute risk increase is small, and subsequent analyses — including a large Nordic cohort study — have produced conflicting results. ACOG (Committee Opinion 717, reaffirmed 2023) states that nitrofurantoin should be reserved for situations where no suitable alternative exists during the first trimester, but it does not classify the drug as contraindicated.

• Late pregnancy (≥36 weeks): Nitrofurantoin can provoke hemolytic anemia in neonates with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Because G6PD status of the fetus is typically unknown, ACOG and most guidelines recommend avoiding nitrofurantoin from 36 weeks onward.

• Practical implication: In the second trimester (approximately 14–35 weeks), nitrofurantoin is widely regarded as a safe and effective first-line choice for uncomplicated cystitis and ASB.

Cephalexin — A Workhorse With a Clean Safety Record

Cephalexin, a first-generation cephalosporin, has decades of pregnancy safety data supporting its use across all trimesters. It is the preferred empirical choice when first-trimester treatment is needed or when nitrofurantoin is contraindicated. Its limitations include a somewhat narrower Gram-negative spectrum and susceptibility to ESBL-producing organisms.

Amoxicillin-Clavulanate — Broad Spectrum, Broad Data

The addition of clavulanate to amoxicillin overcomes much of the β-lactamase-mediated resistance seen with amoxicillin alone. Safety data across pregnancy are reassuring. Gastrointestinal intolerance (particularly diarrhea) is the most common complaint.

Fosfomycin — The Single-Dose Option

Fosfomycin trometamol as a single 3 g oral dose is an attractive option for adherence-challenged patients and has European guideline endorsement for uncomplicated cystitis in pregnancy (EAU/ESCMID). Data in pregnancy are more limited than for the other three agents but generally reassuring. Its primary appeal is the single-dose regimen, which maximizes compliance. Availability and cost vary significantly by region.

§04Dosing and Practical Guidance

Standard Dosing Table for UTI in Pregnancy

Duration considerations:

• For acute cystitis, 3–7 day regimens are standard. Shorter courses (3 days) are often sufficient for cephalexin and amoxicillin-clavulanate in uncomplicated cases; nitrofurantoin is generally prescribed for 5 days minimum.
• For asymptomatic bacteriuria, ACOG recommends a full treatment course (typically 4–7 days), not single-dose therapy (except fosfomycin), followed by a test-of-cure culture one to two weeks after completion.
• Suppressive therapy may be warranted for recurrent UTI (≥2 episodes): nitrofurantoin 50–100 mg nightly for the remainder of pregnancy (avoiding the ≥36-week window) is a commonly used approach.

§05Side Effects and Monitoring

Common Adverse Effects by Agent

Nitrofurantoin: Nausea and vomiting (reduced with macrocrystal formulation and food), headache, flatulence. Rare but serious: pulmonary hypersensitivity (acute or chronic), peripheral neuropathy with prolonged use, hepatotoxicity.

Cephalexin: Diarrhea, nausea, rash. Allergic reactions possible; anaphylaxis rare. Low risk of C. difficile-associated diarrhea.

Amoxicillin-clavulanate: Diarrhea (most common — clavulanate-driven), nausea, vaginal candidiasis. Rash (distinguish from mononucleosis-associated rash). Cholestatic hepatitis (rare, typically reversible).

Fosfomycin: Diarrhea, nausea, headache, vulvovaginitis. Generally well tolerated given the single-dose regimen.

Monitoring Recommendations

• Test-of-cure urine culture 1–2 weeks after completing therapy for ASB (ACOG recommendation). Not routinely required for symptomatic cystitis if symptoms resolve, though many clinicians still obtain one.
• Monthly urine cultures for the remainder of pregnancy after treated ASB or cystitis — recurrence rates reach 20–30%.
• Complete blood count if prolonged nitrofurantoin therapy (suppressive regimen) is used, to monitor for hemolytic anemia.
• Liver function monitoring only if symptoms of hepatotoxicity develop (jaundice, pruritus, right-upper-quadrant pain).

§06Contraindications and Important Interactions

Antibiotics to Avoid in Pregnancy

• Fluoroquinolones (ciprofloxacin, levofloxacin): Associated with cartilage damage in animal studies; human safety data insufficient. Reserved only for resistant pyelonephritis with no alternative.
• Trimethoprim-sulfamethoxazole (TMP-SMX): Trimethoprim is a folate antagonist — associated with neural tube defects in the first trimester. Sulfonamides near term risk neonatal kernicterus. Avoid throughout pregnancy when possible; if used in the second trimester for a resistant organism, concurrent folic acid supplementation is advisable.
• Tetracyclines (doxycycline, minocycline): Tooth discoloration and impaired bone growth when used after 15 weeks of gestation.
• Aminoglycosides (gentamicin, tobramycin): Ototoxicity and nephrotoxicity — reserved for severe pyelonephritis or sepsis under specialist supervision with therapeutic drug monitoring.

§07Special Populations and Considerations

Group B Streptococcus (GBS) Bacteriuria

GBS bacteriuria at any colony count in pregnancy is clinically significant: it identifies heavy vaginal-rectal colonization and mandates intrapartum antibiotic prophylaxis (typically intravenous penicillin G or ampicillin) regardless of later GBS screening results. The GBS bacteriuria itself should be treated in the standard fashion, but the finding must be documented and communicated to the labor and delivery team (ACOG/AAP GBS prevention guidelines).

Recurrent UTI in Pregnancy

Women with two or more UTIs during pregnancy benefit from continuous prophylaxis: nitrofurantoin 50–100 mg nightly or cephalexin 250–500 mg nightly for the remainder of the pregnancy. Post-coital prophylaxis (a single dose after intercourse) is an alternative for women whose episodes are temporally related to sexual activity.

Pyelonephritis in Pregnancy

Pyelonephritis is a medical emergency in pregnancy and generally requires inpatient management with intravenous antibiotics — typically a third-generation cephalosporin (ceftriaxone 1–2 g IV daily) or ampicillin plus gentamicin. Oral step-down therapy follows clinical improvement (afebrile for 24–48 hours). This scenario is beyond the scope of outpatient self-management and should prompt immediate medical evaluation.

Renal Impairment

Nitrofurantoin is ineffective and potentially toxic when creatinine clearance falls below 30 mL/min, as adequate urinary drug concentrations cannot be achieved. β-Lactams (cephalexin, amoxicillin-clavulanate) require dose adjustment in severe renal impairment. Fosfomycin does not require dose adjustment for a single-dose regimen but is not recommended for repeated dosing in significant renal dysfunction.

Penicillin Allergy

True IgE-mediated penicillin allergy affects fewer than 2% of patients who report a penicillin allergy. For patients with non-anaphylactic histories, cephalexin carries a cross-reactivity risk below 2% and is generally safe. For patients with documented anaphylaxis to penicillin, nitrofurantoin (within the appropriate gestational window) or fosfomycin are the recommended alternatives.

§08Red Flags — When to Seek Immediate Medical Care

Pregnant patients with UTI symptoms should contact their healthcare provider promptly. Seek emergency care if any of the following develop:

• Fever ≥38.0 °C (100.4 °F) — suggests ascending infection or pyelonephritis
• Flank or costovertebral angle pain — classic sign of pyelonephritis
• Rigors, chills, or signs of sepsis (tachycardia, hypotension, altered mental status)
• Persistent vomiting preventing oral antibiotic intake
• Vaginal bleeding or uterine contractions — UTI can precipitate preterm labor
• Symptoms worsening or not improving after 48–72 hours of appropriate antibiotic therapy
• Visible hematuria (blood in urine) — may indicate complicated infection or alternative diagnosis

Do not attempt to self-treat a UTI during pregnancy. Even mild symptoms warrant professional evaluation and culture-guided therapy.

§09Frequently Asked Questions

1. Is it safe to take nitrofurantoin in the first trimester?

The evidence is mixed. A small increased risk of certain birth defects has been reported in some epidemiological studies, but the absolute risk remains low. ACOG recommends using nitrofurantoin in the first trimester only when a suitable alternative (such as cephalexin or amoxicillin-clavulanate) is not available. If your clinician prescribes it, the benefits of treating the infection generally outweigh the small potential risk.

2. Can an untreated UTI cause miscarriage or preterm birth?

Untreated bacteriuria — including asymptomatic bacteriuria — is associated with a two- to threefold increased risk of preterm delivery and low birth weight. Pyelonephritis carries additional risks including maternal sepsis. This is why screening and treatment of even symptom-free bacteriuria is standard of care in pregnancy.

3. How soon should I start antibiotics after a positive urine culture?

Treatment should begin promptly. For symptomatic cystitis, empirical therapy is typically started immediately after obtaining the culture, then adjusted based on sensitivity results at 48–72 hours. For asymptomatic bacteriuria identified on screening, treatment should begin as soon as the culture result is confirmed.

4. Is a single dose of fosfomycin as effective as a 7-day course of nitrofurantoin?

Clinical trials suggest comparable efficacy for acute cystitis, with fosfomycin achieving bacteriological cure rates of approximately 75–85% versus 85–95% for nitrofurantoin. Fosfomycin's advantage lies in guaranteed adherence with a single dose. For ASB in pregnancy, evidence supporting fosfomycin single-dose therapy is less robust, and many clinicians prefer longer-course regimens.

5. Will the antibiotic harm my baby?

The antibiotics discussed in this article — cephalexin, amoxicillin-clavulanate, fosfomycin, and nitrofurantoin (in the appropriate gestational window) — are among the best-studied medications in pregnancy and carry low fetal risk. The risk of not treating a UTI in pregnancy is substantially greater than the risk of these antibiotics. Always discuss specific concerns with your prescriber.

6. Do I need a test-of-cure after finishing antibiotics?

For asymptomatic bacteriuria, yes — ACOG recommends a repeat urine culture one to two weeks after completing treatment to confirm eradication. For symptomatic cystitis, a test-of-cure is recommended by many clinicians, particularly given the high recurrence rate during pregnancy.

7. Can cranberry products prevent UTI in pregnancy?

Cranberry products have modest evidence for UTI prevention in non-pregnant women, but data in pregnancy are limited. A Cochrane review found insufficient evidence to recommend cranberry products for UTI prevention in pregnancy. They are not harmful but should not replace antibiotic treatment or prophylaxis when indicated. Adequate hydration and frequent voiding remain reasonable supportive measures.

8. What if my UTI is caused by a resistant organism?

Culture and sensitivity testing will identify effective antibiotic options. For ESBL-producing organisms, fosfomycin or nitrofurantoin (if appropriate for the gestational age) may retain activity. Carbapenem therapy (e.g., ertapenem) may be necessary for multidrug-resistant infections and requires infectious disease consultation.

§10References

1. ACOG. Committee Opinion No. 717: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects. Obstet Gynecol. 2017;130(3):e150–e152. ACOG Committee Opinion 717

2. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2019;(11):CD000490. PMID: 31765489

3. Ailes EC, Gilboa SM, Langlois PH, et al. National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects. Birth Defects Res A Clin Mol Teratol. 2016;106(11):940–949. PMID: 27891788

4. Nordeng H, Lupattelli A, Romøren M, Koren G. Neonatal outcomes after gestational exposure to nitrofurantoin. Obstet Gynecol. 2013;121(2 Pt 1):306–313. PMID: 23344280

5. US Preventive Services Task Force. Screening for asymptomatic bacteriuria in adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(12):1188–1194. PMID: 31550038

6. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the IDSA and ESMID. Clin Infect Dis. 2011;52(5):e103–e120. PMID: 21292654

7. NICE. Urinary tract infection (lower): antimicrobial prescribing. NICE Guideline NG109. 2018. nice.org.uk/guidance/ng109

8. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;(10):CD001321. PMID: 23076891

9. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, CDC. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1–36. PMID: 21088663

10. FDA. Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections. 2016. fda.gov/drugs/drug-safety-and-availability

§11About the Author

Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in medication safety, pharmacotherapy optimization, and drug information. He serves as a senior content author for PillsCard.com, where he translates complex pharmaceutical evidence into accessible, clinically accurate guidance for patients and healthcare professionals worldwide. His work emphasizes evidence-based practice, with particular attention to vulnerable populations including pregnant and breastfeeding women.

§12Medical Disclaimer

This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The content reflects current evidence and guidelines at the time of writing but may not account for individual clinical circumstances, local resistance patterns, or evolving recommendations. Always consult a qualified healthcare professional before starting, stopping, or changing any medication — especially during pregnancy. Do not delay seeking medical care based on information in this article. PillsCard.com and the author assume no liability for actions taken based on this content.